Experienced in Pityriasis Rosea

Dr. Armando E. Acevedo

Pediatrics | General Practice
Acevedo Medical Care Group Inc
2400 Nw 54th St, 
Miami, FL 
Accepting New Patients
Offers Telehealth
Experienced in Pityriasis Rosea
Acevedo Medical Care Group Inc
2400 Nw 54th St, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Armando Acevedo is a primary care provider, a Pediatrics specialist and a General Practice provider in Miami, Florida. Dr. Acevedo is rated as an Experienced provider by MediFind in the treatment of Pityriasis Rosea. His top areas of expertise are Asthma, Obesity, Asthma in Children, and Obesity in Children. Dr. Acevedo is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatrics
General Practice
Licenses
Specialist in FL
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
View 7 Less Insurance Carriers -

Locations

ACEVEDO MEDICAL CARE GROUP INC
2400 Nw 54th St, Miami, FL 33142

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomised, Double-blind, Parallel Group, Multicentre, Stratified, Study Evaluating the Efficacy and Safety of Once Daily Fluticasone Furoate/Vilanterol Inhalation Powder Compared to Once Daily Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Participants Aged 5 to 17 Years Old (Inclusive) Currently Uncontrolled on Inhaled Corticosteroids
A Randomised, Double-blind, Parallel Group, Multicentre, Stratified, Study Evaluating the Efficacy and Safety of Once Daily Fluticasone Furoate/Vilanterol Inhalation Powder Compared to Once Daily Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Participants Aged 5 to 17 Years Old (Inclusive) Currently Uncontrolled on Inhaled Corticosteroids
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drugs: Fluticasone Furoate, Vilanterol
Study Phase: Phase 3
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Biological
Study Phase: Phase 3
Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg Once Daily on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma
Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg Once Daily on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma
Enrollment Status: Completed
Publish Date: January 17, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Terminated
Publish Date: June 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: June 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

1 Total Publications

A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
Journal: The Journal of infectious diseases
Published: July 11, 2024
Similar Doctors
Advanced in Pityriasis Rosea
Dr. Giovanna Ciocca
Dermatology | Pediatrics
Advanced in Pityriasis Rosea
Dr. Giovanna Ciocca
Dermatology | Pediatrics

Ciocca Dermatology PA

7001 Sw 97th Ave, Suite 101, 
Miami, FL 
 (10.9 miles away)
305-273-7998
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Giovanna Ciocca is a Dermatologist and a Pediatrics provider in Miami, Florida. Dr. Ciocca is rated as a Distinguished provider by MediFind in the treatment of Pityriasis Rosea. Her top areas of expertise are Neurocutaneous Melanosis, Giant Congenital Melanocytic Nevus, Familial Atypical Multiple Mole Melanoma Syndrome, and Giant Congenital Nevus. Dr. Ciocca is currently accepting new patients.

Experienced in Pityriasis Rosea
Dr. Serap O. Howarth
Pediatrics | Family Medicine
Experienced in Pityriasis Rosea
Dr. Serap O. Howarth
Pediatrics | Family Medicine
9611 W Broward Blvd, 
Plantation, FL 
 (20.7 miles away)
954-424-7000
Languages Spoken:
English, Japanese, Spanish, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Serap Howarth is a primary care provider, practicing in Pediatrics and Family Medicine in Plantation, Florida. Dr. Howarth is rated as an Advanced provider by MediFind in the treatment of Pityriasis Rosea. Her top areas of expertise are Croup, Hand-Foot-Mouth Disease (HFMD), Trichohepatoenteric Syndrome, and Diarrhea. Dr. Howarth is currently accepting new patients.

Experienced in Pityriasis Rosea
Dr. Gustavo A. Correa
General Practice
Experienced in Pityriasis Rosea
Dr. Gustavo A. Correa
General Practice
Sunrise, FL 
 (22.7 miles away)
954-225-4454
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Gustavo Correa is a primary care provider, practicing in General Practice in Sunrise, Florida. Dr. Correa is rated as an Advanced provider by MediFind in the treatment of Pityriasis Rosea. His top areas of expertise are Obesity in Children, Obesity, Food Allergy, and Osteomyelitis in Children. Dr. Correa is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Acevedo's expertise for a condition
ConditionClose
        View All 53 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile